NR 567 / NR567 FINAL EXAM – ADVANCED
PHARMACOLOGY FOR THE AGACNP | 2
VERSIONS EACH 100 QUESTIONS WITH
ANSWERS & RATIONALES | INSTANT PDF
DOWNLOAD
Core Domains:
• Pharmacokinetics and Pharmacodynamics (Absorption, Distribution,
Metabolism, Elimination, Receptor Theory)
• Autonomic and Cardiovascular Pharmacology (Antihypertensives,
Antiarrhythmics, Heart Failure, Shock)
• Central Nervous System Pharmacology (Sedatives, Antiepileptics,
Neuromuscular Blockers, Pain Management)
• Endocrine and Metabolic Pharmacology (Antidiabetics, Thyroid,
Adrenal, Electrolyte Management)
• Antimicrobial Therapy and Stewardship (Antibiotics, Antifungals,
Antivirals, Resistance)
• Hematology and Coagulation (Anticoagulants, Antiplatelets,
Thrombolytics)
• Pulmonary and Renal Pharmacology (Bronchodilators, Diuretics, Acid-
Base)
• Critical Care and Emergency Pharmacology (Vasopressors, Sedation,
Toxicology)
• Special Populations (Geriatrics, Renal/Hepatic Impairment, Pregnancy,
Pharmacogenomics)
, • Oncology and Immunologic Pharmacology (Chemotherapy,
Immunosuppressants, Biologics)
Introduction
This comprehensive examination is designed for NR 567 Advanced
Pharmacology for the Adult-Gerontology Acute Care Nurse Practitioner
(AGACNP) students preparing for their Final Exam at Chamberlain University.
The assessment evaluates mastery of core pharmacotherapeutic principles
essential for acute care practice, including pharmacokinetics,
pharmacodynamics, clinical decision-making, and evidence-based prescribing
across complex patient populations. This document contains two complete
versions (Version 1 and Version 2), each with 100 exam-style multiple-choice
questions with verified correct answers and detailed clinical rationales. Content
reflects the 2026/2027 academic year curriculum and incorporates updated
guidelines for sepsis management, heart failure therapy, anticoagulation,
antimicrobial stewardship, and pain management. Each question is designed
to challenge clinical reasoning and application of pharmacological knowledge
in acute and critical care settings. Successful completion demonstrates
readiness for independent AGACNP practice and board certification
preparation.
VERSION 1: QUESTIONS 1–100
Question 1
Which parameter primarily determines a drug's volume of distribution (Vd)?
A. Renal clearance
B. Protein binding
C. Lipid solubility and tissue binding
D. Half-life
, C. Lipid solubility and tissue binding
RATIONALE: Vd reflects how extensively a drug distributes into tissues.
Lipophilic drugs with high tissue binding have larger Vd, indicating greater
distribution out of the vascular compartment. Renal clearance affects
elimination, protein binding affects free drug concentration, and half-life
reflects elimination rate.
Question 2
A patient with severe hepatic failure will most likely have which change in
drug pharmacokinetics?
A. Increased renal excretion
B. Decreased oral absorption
C. Reduced metabolism and prolonged half-life of hepatically cleared drugs
D. Increased protein binding
C. Reduced metabolism and prolonged half-life of hepatically cleared
drugs
RATIONALE: Hepatic failure reduces metabolism of drugs cleared by the
liver (e.g., benzodiazepines, opioids, beta-blockers), increasing half-life and
exposure. Dose adjustments are required. Renal excretion is not primarily
affected, absorption changes are variable, and protein binding typically
decreases.
Question 3
A patient is receiving a continuous IV infusion of a drug that follows linear
pharmacokinetics. The steady-state concentration (Css) is 10 mcg/mL at an
infusion rate of 100 mg/hr. If the infusion rate is increased to 200 mg/hr and a
new steady state is reached, what is the approximate Css? (Assume first-order
elimination and no change in clearance.)
, A. 10 mcg/mL
B. 15 mcg/mL
C. 20 mcg/mL
D. 40 mcg/mL
C. 20 mcg/mL
RATIONALE: For linear pharmacokinetics, Css is directly proportional to
the infusion rate (Css = infusion rate / clearance). Doubling the infusion rate
from 100 to 200 mg/hr doubles Css from 10 to 20 mcg/mL.
Question 4
A drug with a high first-pass effect is administered orally. Where is it primarily
metabolized before reaching systemic circulation?
A. Kidneys
B. Lungs
C. Liver
D. Stomach
C. Liver
RATIONALE: First-pass metabolism occurs in the liver. Kidneys excrete
drugs, lungs metabolize some drugs but not primary first-pass, and stomach
absorbs but does not significantly metabolize.
Question 5
A patient receives a drug with a half-life of 4 hours. Approximately how many
hours will it take to reach steady state?
A. 8 hours
B. 12 hours
PHARMACOLOGY FOR THE AGACNP | 2
VERSIONS EACH 100 QUESTIONS WITH
ANSWERS & RATIONALES | INSTANT PDF
DOWNLOAD
Core Domains:
• Pharmacokinetics and Pharmacodynamics (Absorption, Distribution,
Metabolism, Elimination, Receptor Theory)
• Autonomic and Cardiovascular Pharmacology (Antihypertensives,
Antiarrhythmics, Heart Failure, Shock)
• Central Nervous System Pharmacology (Sedatives, Antiepileptics,
Neuromuscular Blockers, Pain Management)
• Endocrine and Metabolic Pharmacology (Antidiabetics, Thyroid,
Adrenal, Electrolyte Management)
• Antimicrobial Therapy and Stewardship (Antibiotics, Antifungals,
Antivirals, Resistance)
• Hematology and Coagulation (Anticoagulants, Antiplatelets,
Thrombolytics)
• Pulmonary and Renal Pharmacology (Bronchodilators, Diuretics, Acid-
Base)
• Critical Care and Emergency Pharmacology (Vasopressors, Sedation,
Toxicology)
• Special Populations (Geriatrics, Renal/Hepatic Impairment, Pregnancy,
Pharmacogenomics)
, • Oncology and Immunologic Pharmacology (Chemotherapy,
Immunosuppressants, Biologics)
Introduction
This comprehensive examination is designed for NR 567 Advanced
Pharmacology for the Adult-Gerontology Acute Care Nurse Practitioner
(AGACNP) students preparing for their Final Exam at Chamberlain University.
The assessment evaluates mastery of core pharmacotherapeutic principles
essential for acute care practice, including pharmacokinetics,
pharmacodynamics, clinical decision-making, and evidence-based prescribing
across complex patient populations. This document contains two complete
versions (Version 1 and Version 2), each with 100 exam-style multiple-choice
questions with verified correct answers and detailed clinical rationales. Content
reflects the 2026/2027 academic year curriculum and incorporates updated
guidelines for sepsis management, heart failure therapy, anticoagulation,
antimicrobial stewardship, and pain management. Each question is designed
to challenge clinical reasoning and application of pharmacological knowledge
in acute and critical care settings. Successful completion demonstrates
readiness for independent AGACNP practice and board certification
preparation.
VERSION 1: QUESTIONS 1–100
Question 1
Which parameter primarily determines a drug's volume of distribution (Vd)?
A. Renal clearance
B. Protein binding
C. Lipid solubility and tissue binding
D. Half-life
, C. Lipid solubility and tissue binding
RATIONALE: Vd reflects how extensively a drug distributes into tissues.
Lipophilic drugs with high tissue binding have larger Vd, indicating greater
distribution out of the vascular compartment. Renal clearance affects
elimination, protein binding affects free drug concentration, and half-life
reflects elimination rate.
Question 2
A patient with severe hepatic failure will most likely have which change in
drug pharmacokinetics?
A. Increased renal excretion
B. Decreased oral absorption
C. Reduced metabolism and prolonged half-life of hepatically cleared drugs
D. Increased protein binding
C. Reduced metabolism and prolonged half-life of hepatically cleared
drugs
RATIONALE: Hepatic failure reduces metabolism of drugs cleared by the
liver (e.g., benzodiazepines, opioids, beta-blockers), increasing half-life and
exposure. Dose adjustments are required. Renal excretion is not primarily
affected, absorption changes are variable, and protein binding typically
decreases.
Question 3
A patient is receiving a continuous IV infusion of a drug that follows linear
pharmacokinetics. The steady-state concentration (Css) is 10 mcg/mL at an
infusion rate of 100 mg/hr. If the infusion rate is increased to 200 mg/hr and a
new steady state is reached, what is the approximate Css? (Assume first-order
elimination and no change in clearance.)
, A. 10 mcg/mL
B. 15 mcg/mL
C. 20 mcg/mL
D. 40 mcg/mL
C. 20 mcg/mL
RATIONALE: For linear pharmacokinetics, Css is directly proportional to
the infusion rate (Css = infusion rate / clearance). Doubling the infusion rate
from 100 to 200 mg/hr doubles Css from 10 to 20 mcg/mL.
Question 4
A drug with a high first-pass effect is administered orally. Where is it primarily
metabolized before reaching systemic circulation?
A. Kidneys
B. Lungs
C. Liver
D. Stomach
C. Liver
RATIONALE: First-pass metabolism occurs in the liver. Kidneys excrete
drugs, lungs metabolize some drugs but not primary first-pass, and stomach
absorbs but does not significantly metabolize.
Question 5
A patient receives a drug with a half-life of 4 hours. Approximately how many
hours will it take to reach steady state?
A. 8 hours
B. 12 hours
